Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus
- PMID: 8887017
- DOI: 10.1016/1056-8727(95)00081-x
Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus
Abstract
The present study was undertaken to investigate the efficacy of a new, highly purified (purity greater than 91%), ethyl esterification product from natural eicosapentaenoic acid (EPA-E, C20:5 omega 3) in patients with type II diabetes mellitus (NIDDM). Hemodynamic changes were assessed at the level of the dorsalis pedis artery using an ultrasonic color Doppler duplex system before and after oral administration of EPA-E at a dose of 1800 mg/day for 48 weeks. The cross-sectional area of the dorsalis pedis artery increased significantly from 2.5 +/- 0.2 to 3.9 +/- 0.4 mm2 (48 weeks, mean +/- SE, p < 0.05). Moreover, EPA-E improved the clinical symptom (coldness, numbness) as well as the vibration perception threshold sense of the lower extremities [from 32.1 +/- 8.5 to 16.1 +/- 4.8 (48 weeks) microns]. A significant decrease of serum triglycerides was also noted by EPA-E administration. Furthermore, significant decrease of the excretion of albumin in urine [from 24.4 +/- 3.3 to 13.9 +/- 1.8 (48 weeks) mg/g.Cr, p < 0.05]. The results of this study suggest that EPA-E has significant beneficial effects on diabetic neuropathy and serum lipids as well as other diabetic complications such as nephropathy and macroangiopathy.
Similar articles
-
Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients.Diabetes Res Clin Pract. 1995 Apr;28(1):35-40. doi: 10.1016/0168-8227(95)01056-j. Diabetes Res Clin Pract. 1995. PMID: 7587910 Clinical Trial.
-
Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension.Am J Clin Nutr. 2002 Nov;76(5):1007-15. doi: 10.1093/ajcn/76.5.1007. Am J Clin Nutr. 2002. PMID: 12399272 Clinical Trial.
-
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.J Am Heart Assoc. 2017 Jul 14;6(7):e004740. doi: 10.1161/JAHA.116.004740. J Am Heart Assoc. 2017. PMID: 28710178 Free PMC article. Clinical Trial.
-
Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.Lipids Health Dis. 2017 Aug 10;16(1):149. doi: 10.1186/s12944-017-0541-3. Lipids Health Dis. 2017. PMID: 28797250 Free PMC article. Review.
-
Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.Am J Ther. 2016 May-Jun;23(3):e905-10. doi: 10.1097/MJT.0000000000000165. Am J Ther. 2016. PMID: 25828517 Review.
Cited by
-
Comparison of the Effects of Omega 3 and Vitamin E on Palcitaxel-Induced Peripheral Neuropathy.Open Access Maced J Med Sci. 2018 Oct 21;6(10):1857-1861. doi: 10.3889/oamjms.2018.333. eCollection 2018 Oct 25. Open Access Maced J Med Sci. 2018. PMID: 30455762 Free PMC article.
-
New Areas of Interest: Is There a Role for Omega-3 Fatty Acid Supplementation in Patients With Diabetes and Cardiovascular Disease?Curr Diab Rep. 2019 Jan 25;19(2):6. doi: 10.1007/s11892-019-1126-5. Curr Diab Rep. 2019. PMID: 30684085 Review.
-
Residual microvascular risk in diabetes: unmet needs and future directions.Nat Rev Endocrinol. 2010 Jan;6(1):19-25. doi: 10.1038/nrendo.2009.213. Nat Rev Endocrinol. 2010. PMID: 19859073 Review.
-
Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.Diabetologia. 2016 Jul;59(7):1422-1429. doi: 10.1007/s00125-016-3966-8. Epub 2016 Apr 22. Diabetologia. 2016. PMID: 27106721 Clinical Trial.
-
Omega 3 fatty acids for prevention and treatment of cardiovascular disease.Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003177. doi: 10.1002/14651858.CD003177.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2018 Jul 18;7:CD003177. doi: 10.1002/14651858.CD003177.pub3. PMID: 15495044 Free PMC article. Updated. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials